An Observational Cohort Study of the Safety of Brentuximab Vedotin in the Treatment of Relapsed or Refractory CD30+ Hodgkin Lymphoma and Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma - ARROVEN
Latest Information Update: 07 Jul 2016
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Anaplastic large cell lymphoma; Hodgkin's disease
- Focus Adverse reactions
- Acronyms ARROVEN
- Sponsors Takeda Oncology
- 14 Oct 2013 New trial record
- 11 Oct 2013 Results have been presented at the 9th International Symposium on Hodgkin Lymphoma (ISHL) according to a : Seattle Genetics media release.